PMID- 38312210 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240206 IS - 1178-7007 (Print) IS - 1178-7007 (Electronic) IS - 1178-7007 (Linking) VI - 17 DP - 2024 TI - Association of Circulating Carbohydrate Antigen 19-9 Level with Type 2 Diabetic Kidney Disease in Chinese Adults: A Cross-Sectional Study. PG - 467-477 LID - 10.2147/DMSO.S434972 [doi] AB - OBJECTIVE: Very few and conflicting data are available regarding the correlation between circulating carbohydrate antigen 19-9 (CA19-9) levels and diabetic kidney disease (DKD) and its components including albuminuria and a low estimated glomerular filtration rate (eGFR). This study aimed to examine the association of circulating CA19-9 and DKD in Chinese patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 402 hospitalized T2DM patients between September 2017 and December 2021 were included in this cross-sectional study. There were 224 and 178 subjects in non-DKD and DKD groups, respectively. Serum CA19-9 was measured by chemiluminescence method, and its potential relationship with DKD was evaluated by multivariate logistic regression and correlation analyses, and receiver operating characteristic (ROC) curve analysis. RESULTS: T2DM patients with DKD had significantly higher serum CA19-9 levels than those without, and serum CA19-9 levels were positively related to urinary albumin-to-creatinine ratio and negatively to eGFR (P<0.01). Multivariate regression analysis revealed that serum CA 19-9 was an independent factor of DKD [odds ratio (OR), 1.018; 95% confidence interval (CI), 1.002-1.035; P<0.05]. Moreover, an increased progressively risk of DKD with an increase in serum CA19-9 quartiles was observed (P for trend <0.001), and T2DM patients in the highest serum CA19-9 quartile were associated with an increased likelihood of DKD when compared to those in the lowest quartile (OR: 2.936, 95% CI 1.129-7.633, P<0.05). Last, the analysis of ROC curves suggested that serum CA 19-9 at a cut of 25.09 U/mL resulted in the highest Youden index with sensitivity 43.8% and 75.4% specificity to predict the presence of DKD. CONCLUSION: These results showed that high circulating CA19-9 was related to DKD and may serve as a useful biomarker of DKD in hospitalized Chinese T2DM patients. CI - (c) 2024 Yan et al. FAU - Yan, Pijun AU - Yan P AUID- ORCID: 0000-0001-6692-2401 AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Li, Jia AU - Li J AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Zhang, Yi AU - Zhang Y AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Dan, Xiaofang AU - Dan X AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Wu, Xian AU - Wu X AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Zhang, Xing AU - Zhang X AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Yang, Yuxia AU - Yang Y AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Chen, Xiping AU - Chen X AD - Clinical medical College, Southwest Medical University, Luzhou, People's Republic of China. FAU - Li, Shengxi AU - Li S AD - Clinical medical College, Southwest Medical University, Luzhou, People's Republic of China. FAU - Chen, Pan AU - Chen P AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Wan, Qin AU - Wan Q AUID- ORCID: 0000-0001-7765-1416 AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. FAU - Xu, Yong AU - Xu Y AD - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China. AD - Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, People's Republic of China. AD - Sichuan Clinical Research Center for Nephropathy, Luzhou, People's Republic of China. AD - Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, People's Republic of China. LA - eng PT - Journal Article DEP - 20240131 PL - New Zealand TA - Diabetes Metab Syndr Obes JT - Diabetes, metabolic syndrome and obesity : targets and therapy JID - 101515585 PMC - PMC10838495 OTO - NOTNLM OT - Chinese population OT - carbohydrate antigen 19-9 OT - diabetic kidney disease OT - estimated glomerular filtration rate OT - urinary albumin-to-creatinine ratio COIS- The authors report no conflicts of interest in this work. EDAT- 2024/02/05 06:42 MHDA- 2024/02/05 06:43 PMCR- 2024/01/31 CRDT- 2024/02/05 04:15 PHST- 2023/09/18 00:00 [received] PHST- 2024/01/16 00:00 [accepted] PHST- 2024/02/05 06:43 [medline] PHST- 2024/02/05 06:42 [pubmed] PHST- 2024/02/05 04:15 [entrez] PHST- 2024/01/31 00:00 [pmc-release] AID - 434972 [pii] AID - 10.2147/DMSO.S434972 [doi] PST - epublish SO - Diabetes Metab Syndr Obes. 2024 Jan 31;17:467-477. doi: 10.2147/DMSO.S434972. eCollection 2024.